Clicky

ADC Therapeutics SA(ADCT) News

Date Title
Aug 1 Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
Jul 30 ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
Jun 27 ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
May 30 ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 15 ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 10 ADC Therapeutics First Quarter 2024 Earnings: In Line With Expectations
May 9 Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT)
May 9 ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
May 9 ADC Therapeutics SA (NYSE:ADCT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 7 ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript
May 6 ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
May 6 ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
May 6 ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial
May 6 ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 6 ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
May 1 ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
Apr 4 ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Apr 3 ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
Apr 1 ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Mar 16 US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results